Neuralink Targets Mass Brain Implant Production by 2026
Neuralink is preparing for a major scale-up of its brain-computer interface programme, with plans to increase production and automate surgical procedures in the coming years. The move signals a shift from early trials toward broader deployment of its implant technology.
Move toward mass production and automation
In 2026, Neuralink plans to begin high-volume manufacturing of its brain implants. At the same time, the company intends to transition to a fully automated surgical process. As a result, implantation could become faster and more consistent. Moreover, automation may help reduce reliance on specialised surgical teams as the programme expands.
Human trials and early use cases
The brain implant targets people with conditions such as spinal cord injuries. Since trials began, users have demonstrated the ability to interact with digital devices through thought alone. For example, participants have used the implant to control cursors, browse the internet, and operate software. Meanwhile, Neuralink started human testing in 2024 after resolving safety concerns raised earlier by the U.S. Food and Drug Administration. That approval marked a critical step forward after an initial rejection in 2022.
Growth, funding, and current reach
By late 2025, Neuralink had implanted devices in 12 people worldwide with severe paralysis. Consequently, the company has gathered real-world data on both digital and physical tool control. In addition, a $650 million funding round in June strengthened its financial position. Therefore, with regulatory clearance, active trials, and new capital, Neuralink appears positioned to accelerate development as it moves toward larger-scale deployment.
